A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19

Zhongchao Wang; Dewei Zhang; Shengming Wang; Yanhua Jin; Jianbo Huan; Yue Wu; Cheng Xia; Zhe Li; Xingshun Qi; Duanzhen Zhang; Xiumin Han; Xianyang Zhu; Ying Qu; Qiguang Wang

doi:10.12659/MSM.926651

24 September 2020: Clinical Research

A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19

Zhongchao Wang ^1ABCDEFG* , Dewei Zhang ^2BC* , Shengming Wang ^3BC* , Yanhua Jin ^2BC* , Jianbo Huan ^4BC* , Yue Wu ^5CDF* , Cheng Xia ^2CD , Zhe Li ^6B , Xingshun Qi ^7CF , Duanzhen Zhang ^8DF , Xiumin Han ^8DF , Xianyang Zhu ^8DEF , Ying Qu ^9ABCDEFG* , Qiguang Wang ^8ACDEFG*

DOI: 10.12659/MSM.926651

Med Sci Monit 2020; 26:e926651

Authors information Article notes Copyright and License information

View HTML version

Figure 1 Survival analysis before (A) and after (B) propensity score matching of COVID-19 patients complicated with hypertension. ACEIs – angiotensin-converting enzyme inhibitors; ARBs – angiotensin II receptor blockers.

Back to the Article

A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19

Your Privacy